Rather than speculating on ”news” provided by a company which cannot be reached by telephone AND which has a CEO where there is absolutely no information on the internet in relation to this persons biotech competencies AND who outsources development to a dissolved company no one has ever heard about AND is on the FINMA black list then I base my statements on facts available in the public domain – provided by public authorities!
The Ventana patent application on the weight loss chewing gum is a combination of Hoodia and 2-hydroxy oleic acid. The hoodia patent family belongs to the UK AIM listed company Phytopharm. Phytopharm has not disclosed any exploitation agreement with Ventana. Regarding the 2-hydroxyoleic acid rights the following is stated by the inventor, professor Pablo Escriba. (if in doubt check the inventor,the rights and claims on the EPO website)
Pablo Escribá Says:
February 5th, 2010 at 6:19 pm
I am the inventor of 2-hydroxyoleic acid, the star product of Ventana. The University of the Balearic Islands holds the rights for pharmaceutical and nutraceutical applications of this compound around the world, which have been licensed to Lipopharma, BTSA and BBR. Three patents with priority dates
of 2001, 2003 and 2008 interfere with Ventana’s claims of invention. Please see the paper by my research group published in the International Journal of Obesity (Vogler and cols., 2008) and our patents in Lipopharma’s website (www.lipopharma.com). These guys DO NOT OWN THE RIGHTS to market 2-hydroxyoleic acid to treat obesity and related disorders. Ventana’s investors are burning their funds in a hoax company whose main patent recently filed cannot be granted.